[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peri-implantitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peri-implantitis":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,47,0,25,[9,51,81,109,137,166,188,212,242,263,287,310,336,357,380,404,426,451,477,506,530,550,572,596,619],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100448702","investigation-of-biofilm-formation-on-temporary-push-on-rings-of-implant-crowns-100448702",false,"NCT05122897","Investigation of Biofilm Formation on Temporary push-on Rings of Implant Crowns","Temporary push-on Rings of Antimicrobial Alloys for Transmucosal Implant Abutment Systems: a Randomized Clinical Study on Early and Mature Biofilm Formation","Inclusion Criteria:\n\n* Informed Consent signed by the subject\n* Presence of one or more bone level titanium implant prior to insertion of the final restoration\n* No systemic illness\n* No heavy smoking (smoking \\\u003C10 cigarettes\u002Fday)\n* No pregnancy\n* No active periodontitis (probing pocket depth ≤4 mm)\n* No pharmacological treatment or antibiotic therapy during or up to three months before the study\n\nExclusion Criteria:\n\n* Systemic illness (e.g. Diabetes)\n* Heavy smoking (smoking \\>10 cigarettes\u002Fday)\n* Known or suspected non-compliance, drug or alcohol abuse\n* Pregnancy\n* Active periodontitis (probing pocket depth \\>4 mm)\n* Pharmacological treatment or antibiotic therapy during or up to three months before the study",true,"ALL","18 Years",{"count":21,"type":22},33,"ESTIMATED","INTERVENTIONAL",[25],"NA","This in-vivo study investigates early (48h), mature (2 weeks) and long-term (3 months) biofilm formation and composition on temporary push-on cones (exchangeable conical rings) made of noble-alloy-based materials (Pagalinor, PA) in comparison to Titanium-6Aluminum-7Niobium alloy (TAN) presently used in the transmucosal portion of dental implant abutments.",[28,29,30],"Dental Plaque","Oral Biofilm","Peri-implantitis",[32,33,34,35,36,37],"Titanium-6Aluminum-7Niobium alloy","Pagalinor","transmucosal implant abutment","implant crowns","temporary push-on rings","Variobase abutments","RECRUITING","2026-08-10",{"date":41,"type":42},"2026-08-11","ACTUAL",{"date":44,"type":42},"2022-01-11",{"date":46,"type":22},"2026-12-31",{"name":48,"class":49},"University Hospital, Basel, Switzerland","OTHER",1,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":78,"locationsCount":50},"100517459","antibacterial-photodynamic-therapy-in-the-management-of-peri-implantitis-100517459","NCT06017817","Antibacterial Photodynamic Therapy in the Management of Peri-implantitis","Regular Home-use of Antibacterial Photodynamic Therapy in the Management of Peri-implantitis","Inclusion Criteria:\n\n* PPD ≥6 mm and marginal bone loss \\>3 mm\n* Dental implants collected and clinically characterized according to Lähteenmäki et al. CEDR-22\n* Agreement to participate in the study and to sign a written consent form\n* Able to co-operate with the treatment protocol and avoid any other oral hygiene measures outside of the study protocol\n\nExclusion Criteria:\n\n* Presence of any physical limitation or restriction that might restrict Lumoral use\n* Unwilling to participate in the study\n* Pregnancy or lactation\n* Active smoking\n* Medicated diabetes mellitus (DM)\n* Any systemic disease (e.g., wound healing dysfunctions) that could alter the progression of peri-implantitis\n* Use of antibiotics and doxycycline, chlorhexidine, and bisphosphonates, within 4 weeks week prior to study participation\n* Peri-implant and periodontal treatment within 3 months prior to study participation\n* Removable major prosthesis or major orthodontic appliance","85 Years",{"count":60,"type":22},80,[25],"This early-stage study is designed to determine the efficacy of the Lumoral method in periimplantitis. Improved supragingival plaque control can help to also sustain subgingival plaque management in the long term. In addition, the device might have a photobiomodulation effect on periodontal tissues, thus impacting osseointegration.",[64,65],"Peri-Implantitis","Plaque, Dental",[67,68,69,70,71],"Lumoral","Lumorinse","Antibacterial photodynamic therapy (aBPT)","aMMP-8","Plaque control","2026-08-04",{"date":74,"type":42},"2026-08-07",{"date":76,"type":42},"2024-05-13",{"date":46,"type":22},{"name":79,"class":80},"Koite Health Oy","INDUSTRY",{"id":82,"slug":83,"hasResults":12,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":17,"sex":18,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":93,"conditions":94,"keywords":97,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":50},"100650570","impact-of-smoking-on-immune-responses-in-peri-implant-health-and-disease-100650570","NCT07750171","Impact of Smoking on Immune Responses in Peri-implant Health and Disease","Impact of Smoking on Th1\u002FTh2-M1\u002FM2 Cytokine Balance and B-Cell Immune Responses in Peri-Implant Health and Disease","Inclusion Criteria:\n\n* willingness to participate in the study;\n* having at least one dental implant that has been in function for at least one year;\n* having an implant diagnosed with peri-implant health, peri-implant mucositis, or initial peri-implantitis according to the study definitions; for the initial peri-implantitis group, having an implant with PD of 6-7 mm.\n\nExclusion Criteria:\n\n* having received periodontal therapy, oral decontamination treatment, antibiotics, or steroids within the last six months before study initiation;\n* being pregnant or breastfeeding;\n* having rheumatoid arthritis, lupus erythematosus, or poorly controlled systemic diseases such as diabetes or hypertension;\n* having a history of radiation therapy or cancer therapy.","21 Years","75 Years",{"count":91,"type":22},216,"OBSERVATIONAL","Peri-implant diseases are inflammatory conditions affecting the gums and bone around dental implants. Peri-implant mucositis causes inflammation in the gums, while peri-implantitis can also lead to bone loss and, in severe cases, implant failure. Smoking is an important risk factor for these conditions because it may change how the immune system responds to inflammation and infection.\n\nThis study will compare smokers and non-smokers with healthy dental implants, peri-implant mucositis, or peri-implantitis. Fluid samples will be collected from around the implants to measure proteins involved in inflammation, healing, and immune responses. The aim is to better understand how smoking affects the body's response to peri-implant diseases and to identify biological markers that may help assess disease risk and severity in the future.",[95,96,30],"Peri-Implant Health","Peri Implant Mucositis",[30,98,99],"Host immune response","Smoking","2026-08-03",{"date":102,"type":42},"2026-08-06",{"date":104,"type":42},"2026-06-01",{"date":106,"type":22},"2026-12-01",{"name":108,"class":49},"Gazi University",{"id":110,"slug":111,"hasResults":12,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":23,"phases":120,"briefSummary":121,"conditions":122,"keywords":124,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":50},"100648421","study-on-the-treatment-of-dental-implants-using-the-ambijet-system-for-peri-implantitis-and-peri-implant-mucositis-100648421","NCT07722715","Study on the Treatment of Dental Implants Using the AmbiJet System for Peri-implantitis and Peri-implant Mucositis","Randomized, Controlled, Exploratory Study on the Treatment of Dental Implants Using the AmbiJet System for Peri-implantitis and Peri-implant Mucositis (AmbiJet-FIH)","AmbiJet-FIH","Inclusion Criteria:\n\nGeneral criteria:\n\n* Men or women aged \\>= 18 and \\\u003C= 65 years.\n* For women of childbearing age: a form of contraception recognized by conventional medicine during the study.\n* Written consent has been obtained from each patient for the study.\n\nDental criteria:\n\n* Current X-ray of the implant region available (\\\u003C= 6 months prior to first treatment).\n* One to five implants with bone loss from the start of the part of the implant intended for osseointegration (X-ray findings).\n* Bleeding and\u002For suppuration after or without probing at the implant in question (peri-implant mucositis\u002Fperi-implantitis).\n* Clinical signs of inflammation (swelling, redness, soft tissue) on the implant in question (peri-implant mucositis\u002Fperi-implantitis).\n* Average oral hygiene (i.e., brushing teeth at least twice a day).\n\nExclusion Criteria:\n\nGeneral criteria:\n\n* Known allergies to materials used in the study (gold, copper, polyimide).\n* Diabetes (type I or type II), vasculitis, osteoporosis, osteomalacia.\n* Smokers (\\>1 cigarette\u002Fweek).\n* Use of medications to modulate bone metabolism (e.g., bisphosphonates).\n* Eating disorders such as bulimia or anorexia nervosa.\n* Use of antibiotics within the last 2 months prior to the start of the study.\n* Application of local antibiotics in the oral cavity within the last 2 months prior to the start of the study.\n* Use of antimicrobial mouthwashes within the last month before the start of the study.\n* Anti-inflammatory medication within the last month before the start of the study.\n* Pregnancy or breastfeeding.\n* Alcoholism or drug abuse.\n* Wound healing disorders.\n* Immunosuppression.\n* Condition following insertion of an electrical, electrically active, or electronic implant.\n\nDental criteria:\n\n* An implant with bone loss \\>6 mm from the start of the part of the implant intended for osseointegration (X-ray findings) (peri-implantitis).\n* Pathological changes in the oral mucosa or gingiva, such as oral lichen planus, chronic recurrent aphthae, melanotic macula, precancerous lesions (e.g., leukoplakia), melanomas.\n* Use of medically unacceptable types of treatment, therapies, or substances (off-label use of treatments for peri-implant mucositis or peri-implantitis).","65 Years",{"count":119,"type":22},26,[25],"Inflammation of the tissue surrounding a dental implant (peri-implantitis or peri-implant mucositis) can lead to implant loss in advanced stages. The AmbiJet system utilizes cold atmospheric plasma (CAP), a physical procedure with a strong antibacterial effect. This clinical trial investigates whether the additional application of cold plasma directly on the patient following conventional mechanical cleaning of the implants is safe, well-tolerated, and resolves inflammation more quickly compared to standard treatment.",[96,123],"Peri Implantitis",[125,126,127],"Plasma Medicine","Cold Atmospheric Plasma","AmbiJet","2026-07-23",{"date":130,"type":42},"2026-07-24",{"date":132,"type":42},"2026-02-14",{"date":134,"type":22},"2026-11-20",{"name":136,"class":80},"Freiburger Medizintechnik GmbH",{"id":138,"slug":139,"hasResults":12,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":146,"conditions":147,"keywords":148,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":50},"100645948","relationship-between-metrnl-expression-il-1-and-tnf--in-patients-with-peri-implantitis-100645948","NCT07697729","Relationship Between Metrnl Expression, IL-1β, and TNF-α in Patients With Peri-Implantitis","Association of Metrnl Expression With IL-1β and TNF-α in Patients With Peri-Implantitis: Potential as a Novel Biomarker","Inclusion Criteria:\n\n* Individuals aged 18 years or older\n* Individuals without systemic disease\n* Individuals with at least one healthy implant or one implant affected by peri-implantitis\n* At least 1 year having elapsed since placement of the prosthetic restoration on the relevant implant\n\nExclusion Criteria:\n\n* Pregnant or lactating individuals.\n* Current smokers.\n* Use of antibiotics or corticosteroids within the previous 6 months.\n* Presence of an implant-supported removable prosthesis.\n* Periodontal or peri-implant treatment within the previous 6 months.",{"count":145,"type":22},60,"Peri-implantitis is an inflammatory disease affecting the tissues around dental implants and may lead to progressive bone loss and implant failure. Current diagnosis is mainly based on clinical and radiographic findings, which may not fully reflect the underlying inflammatory activity. Therefore, there is a need for biological markers that may provide additional information about disease-related changes.\n\nThis observational study aims to compare the levels of Meteorin-like protein (Metrnl) and selected inflammatory cytokines in peri-implant crevicular fluid obtained from individuals with peri-implantitis and individuals with healthy implants. The study will evaluate Metrnl, interleukin-1 beta (IL-1β), tumor necrosis factor-alpha (TNF-α), and interleukin-10 (IL-10). It will also examine the relationships between Metrnl and these inflammatory markers.\n\nThe study hypothesis is that Metrnl levels differ between healthy peri-implant tissues and peri-implantitis and are associated with pro-inflammatory and anti-inflammatory cytokine levels. The findings may help clarify the possible role of Metrnl in peri-implant inflammation and its potential as a biomarker for distinguishing peri-implant health from peri-implantitis.",[30],[149,150,151,152,153,154,155],"Meteorin-Like Protein","Metrnl","Peri-Implant Crevicular Fluid","Interleukin-1 Beta","Tumor Necrosis Factor-Alpha","Interleukin-10","Dental Implants","NOT_YET_RECRUITING","2026-07-09",{"date":159,"type":42},"2026-07-13",{"date":161,"type":22},"2026-07-07",{"date":163,"type":22},"2026-08-02",{"name":165,"class":49},"Ataturk University",{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":23,"phases":175,"briefSummary":176,"conditions":177,"keywords":178,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":4},"100595423","regenerative-outcomes-for-peri-implant-bony-defects-using-amnion-chorion-barrier-vs-collagen-membrane-100595423","NCT07032259","Regenerative Outcomes for Peri-implant Bony Defects Using Amnion-chorion Barrier vs. Collagen Membrane","Regenerative Outcomes for Peri-implant Bony Defects Using Amnion-chorion Barrier vs. Collagen Membrane: a Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Systemically healthy adults (≥18 years) with a diagnosed peri-implantitis lesion requiring surgical intervention of any ethnicity\n* Comprehension of treatment plan and research project.\n* Presence of a single implant in function for at least one year.\n* Radiographic evidence of peri-implant bone loss not exceeding one-third of the implant length.\n* 2-3 wall defects amenable to guided bone regeneration (GBR).\n* Screw-retained, posterior, self-cleansing implant prosthesis.\n* Commitment to maintaining oral hygiene and attending follow-up visits.\n\nExclusion Criteria:\n\n* Patients who have had a history of periodontitis, diabetes, smoking habit, or have been prescribed medications that may interfere with bone healing and metabolism\n* Patients with allergies to any treatment devices\n* Patients who have a lack of keratinized mucosa (\\\u003C2 mm), or positioning for implants or restorative designs that compromise oral hygiene\n* Peri-implant bone defects not attributable to peri-implantitis (e.g. surgical iatrogenic, trauma)\n* Anterior implant restorations (#'s 6-11, #'s 22-27) or cement-retained restorations",{"count":174,"type":22},56,[25],"The purpose of this study is to compare the clinical and radiographic outcomes of two different barrier membranes-amnion-chorion membranes (ACM) and conventional collagen membranes-used in guided bone regeneration (GBR) procedures for the treatment of peri-implantitis. Both membranes are commonly used in clinical practice; however, this study aims to determine whether ACM offers greater benefits in terms of peri-implant probing depth reduction, radiographic bone fill, and patient-reported post-operative healing outcomes. The findings may help inform surgical decision-making and support the use of ACM as a more effective regenerative material for managing peri-implant bony defects.",[64],[30],"2026-07-08",{"date":181,"type":42},"2026-07-10",{"date":183,"type":22},"2026-12",{"date":185,"type":22},"2027-12",{"name":187,"class":49},"Loma Linda University",{"id":189,"slug":190,"hasResults":12,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":195,"targetDuration":197,"studyType":92,"phases":4,"briefSummary":198,"conditions":199,"keywords":200,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":205,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":50},"100646317","patient-perspectives-throughout-peri-implantitis-treatment-100646317","NCT07694323","Patient Perspectives Throughout Peri-Implantitis Treatment","Patient-Centered Outcomes Throughout Peri-Implantitis Therapy: A Multicenter Prospective Observational Study","Inclusion Criteria:\n\n* Adults (≥18 years) diagnosed with peri-implantitis according to the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions (Berglundh et al., 2018).\n* Implants presenting bleeding on probing (BoP) and\u002For suppuration on probing (SoP), increased probing depth, and progressive bone loss compared with previous records.\n\nWhen previous records are unavailable, implants will be included if they present bleeding and\u002For suppuration on gentle probing, probing depth ≥6 mm, and a bone level ≥3 mm apical to the most coronal portion of the rough implant surface.\n\n\\- For patients requiring multiple peri-implantitis surgeries, only the first surgical intervention will be included.\n\nExclusion Criteria:\n\n* Patients who, following non-surgical peri-implantitis treatment, present ≤1 site with isolated bleeding on probing, no suppuration on probing, probing depths ≤5 mm, and no progressive bone loss compared with pretreatment bone levels.\n* Contraindications to surgical peri-implantitis treatment, including plaque index \\>20% and bleeding on probing \\>10%.\n* Previous radiotherapy to the head and neck region.\n* Uncontrolled diabetes mellitus\u002Fhyperglycaemia (HbA1c \\>7%).\n* Pregnancy or breastfeeding at the time of enrollment.\n* Alcohol or substance abuse.\n* Previous surgical treatment of peri-implantitis at the same implant.\n* Inability to complete the postoperative pain assessment (VAS) or the oral health-related quality of life (OHRQoL) questionnaires.",{"count":196,"type":22},45,"1 Year","To evaluate longitudinal changes in oral health-related quality of life (OHRQoL) and other patient-reported outcomes (PROMs) throughout the different stages of peri-implantitis therapy, including diagnosis, non-surgical treatment, surgical treatment, and 6-month follow-up. Secondarily, to explore the influence of clinical, implant-related, and surgical factors on patient-reported outcomes and treatment experience.",[30],[30,201,202,203,204],"Patient-centered outcomes","Oral health-related quality of life","Dental implants","Patient satisfaction",{"date":157,"type":42},{"date":207,"type":22},"2026-09-03",{"date":209,"type":22},"2028-03-30",{"name":211,"class":49},"University of Barcelona",{"id":213,"slug":214,"hasResults":12,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":220,"enrollmentInfo":221,"targetDuration":4,"studyType":23,"phases":223,"briefSummary":224,"conditions":225,"keywords":227,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":235,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":50},"100599760","natural-bioactive-gel-for-peri-implantitis-100599760","NCT07088679","Natural Bioactive Gel for Peri-Implantitis","Efficacy of a Natural Bioactive Gel as an Adjunct to Standard Therapy in the Treatment of Peri-Implantitis: A Randomized Controlled Split-Mouth Clinical Trial","PERISTER","Inclusion Criteria:\n\n* Patients aged between 18 and 70 years\n* Presence of peri-implantitis involving at least two dental implants located in different quadrants\n* Presence of bleeding and\u002For suppuration on probing\n* Increased probing depth (PD) and radiographic bone loss compared to previous examinations\n* In the absence of previous clinical data: PD ≥ 6 mm and bone loss ≥ 3 mm apically from the coronal portion of the intraosseous implant area (radiographically assessed)\n* Willingness and ability to comply with study protocol and follow-up visits\n* Written informed consent provided\n\nExclusion Criteria:\n\n* Patients with cardiac pacemakers or other implanted electronic devices\n* Neurological or psychiatric disorders that may interfere with study participation\n* Systemic diseases, metabolic disorders, or autoimmune conditions\n* Pregnancy or lactation Current participation in other clinical trials","70 Years",{"count":222,"type":22},20,[25],"This study is a randomized controlled clinical trial using a split-mouth design to evaluate the effectiveness of a natural bioactive gel (Sterify Gel®) as an adjunct to standard non-surgical therapy for peri-implantitis. Peri-implantitis is an inflammatory disease that affects the tissues around dental implants and can lead to bone loss and implant failure. The goal of the study is to determine whether the application of Sterify Gel®, which contains polyvinyl polymers, hydroxytyrosol, magnesium ascorbyl phosphate, and nisin, can improve clinical outcomes when used in addition to conventional mechanical debridement and air-polishing.\n\nThe trial will include 20 patients, each with at least two implants in different quadrants affected by peri-implantitis. One implant will be treated with standard therapy plus the gel (test site), while the other will receive standard therapy alone (control site). Clinical outcomes will be measured over a 9-month period, including plaque levels, bleeding on probing, probing depth, suppuration, and bone loss. The results will help assess whether this gel enhances the effectiveness of routine non-surgical peri-implantitis treatment.",[30,155,226],"Non-surgical Periodontal Therapy",[30,203,228,229,230,231,232,233,234],"Bioactive gel","Sterify Gel","Non-surgical therapy","Split-mouth design","Oral biofilm","Mechanical debridement","Randomized controlled trial",{"date":157,"type":42},{"date":237,"type":42},"2025-07-30",{"date":239,"type":22},"2026-12-15",{"name":241,"class":49},"University of Pavia",{"id":243,"slug":244,"hasResults":12,"nctId":245,"briefTitle":246,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":12,"sex":18,"minAge":249,"maxAge":117,"enrollmentInfo":250,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":251,"conditions":252,"keywords":253,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":50},"100645290","non-surgical-treatment-of-peri-implant-pockets-with-h42-100645290","NCT07680491","Non-surgical Treatment of Peri-implant Pockets With H42","H42","Inclusion Criteria:\n\n* Men or women with age ≥ 25 and ≤ 65 years.\n* Subjects affected by peri-implant pockets with probing depth (PD) in the range between 6 to 8 mm.\n* Each subject can have from 1 to 5 defects.\n* Subjects willing to provide signed informed consent to clinical investigation participation.\n\nExclusion Criteria:\n\n* Use of aspirin and antiplatelet agents a week before treatment.\n* Subjects smokers ≥ 10 cigarettes per day.\n* Subjects presenting current or previous bleeding disorders.\n* Subjects taking or having indications for anticoagulant therapy.\n* Concomitant treatments or procedures to improve gum health over the last six months before the clinical investigation enrolment, such as HA gel treatments, injection of fillers, and surgery.\n* Subjects suffering from infectious diseases, including herpes simplex infection, active hepatitis, or human immunodeficiency virus.\n* Subjects with dental aesthetic surgery in the preceding 12 months before the clinical investigation enrolment.","25 Years",{"count":174,"type":22},"This prospective, observational study evaluates the efficacy and safety of H42 non-surgical treatment for peri-implant pockets. The trial involves 56 patients, with 28 subjects receiving the H42 treatment and 28 acting as a control group to monitor soft tissue healing and bone level changes.\n\nClinical outcomes focus on Pocket Probing Depth (PPD) and Silness and Löe Plaque Index (PI) measured at baseline, 1 month, and 3 months. Gingival inflammation, pain intensity on a 0-10 NRS scale, and absence of infection are monitored at baseline, 7, 14, and 21 days, and at 1 and 3 months. Additionally, a five-point tissue assessment evaluates color, suppuration, granulation tissue, bleeding, and incision margins. Radiographic analysis at baseline and 3 months uses standardized periapical x-rays to measure bone level, intra-bony defect height, width, and angulation. Safety is assessed through the continuous registration of adverse events.",[30],[247],"2026-07-01",{"date":256,"type":42},"2026-07-02",{"date":258,"type":42},"2025-12-03",{"date":260,"type":22},"2027-09-30",{"name":262,"class":80},"Bioteck S.p.A.",{"id":264,"slug":265,"hasResults":12,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":23,"phases":271,"briefSummary":272,"conditions":273,"keywords":274,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":286},"100641951","electrolytic-surface-decontamination-in-the-surgical-treatment-of-peri-implantitis-a-randomized-clinical-trial-100641951","NCT07644975","Electrolytic Surface Decontamination in the Surgical Treatment of Peri-implantitis: A Randomized Clinical Trial","Effectiveness of Electrolytic Surface Decontamination in the Surgical Treatment of Peri-Implantitis: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\nAdults aged 18 years or older Diagnosis of peri-implantitis requiring surgical treatment Presence of at least one dental implant diagnosed with peri-implantitis Ability and willingness to attend follow-up visits Provision of written informed consent\n\nExclusion Criteria:\n\nPregnancy or lactation Uncontrolled systemic diseases that may affect healing Immunosuppressive therapy History of head and neck radiotherapy Current use of medications known to affect bone metabolism Inability to comply with the study protocol or follow-up schedule Previous surgical treatment of peri-implantitis at the study implant site",{"count":60,"type":22},[25],"The goal of this clinical trial is to learn whether adjunctive electrolytic surface decontamination can improve the outcomes of surgical treatment of peri-implantitis. The main questions it aims to answer are:\n\n* Does electrolytic surface decontamination reduce probing pocket depth more effectively than conventional surgical treatment alone?\n* Does electrolytic surface decontamination improve bleeding on probing, suppuration, and radiographic bone levels?\n\nResearchers will compare conventional surgical treatment plus electrolytic surface decontamination with conventional surgical treatment alone.\n\nParticipants will:\n\n* Receive surgical treatment for peri-implantitis\n* Be randomly assigned to one of the two treatment groups\n* Attend follow-up visits for clinical and radiographic examinations\n* Undergo assessment of probing pocket depth, bleeding on probing, suppuration, and bone level changes during follow-up",[30],[30,275,276],"Electrolytic Surface Decontamination","Implant Surface Decontamination","2026-06-09",{"date":279,"type":42},"2026-06-12",{"date":281,"type":22},"2026-08-01",{"date":283,"type":22},"2029-08-01",{"name":285,"class":49},"Istanbul University",2,{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":295,"conditions":296,"keywords":297,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":50},"100636726","investigation-of-macrophage-polarization-in-peri-implant-health-and-peri-implantitis-100636726","NCT07569432","Investigation of Macrophage Polarization in Peri-implant Health and Peri-implantitis","Inclusion Criteria:\n\n* Individuals who is suitable for the peri-implantitis diagnosis according to the classifications of periodontal and peri-implant diseases and conditions established in 2017.\n* Individuals with at least one bone-level dental implant and scheduled to undergo exposure surgery.\n\nExclusion Criteria:\n\n* prior peri-implantitis surgery\n* being diagnosed with autoimmune disease, genetic disorders, bone metabolism disorders, poorly controlled systemic diseases (such as diabetes or hypertension)\n* pregnancy or lactation\n* having a history of oral malignancy, chemotherapy or radiotherapy\n* use of anti-inflammatory drugs within 2 weeks, antibiotics within 3 months,\n* need for prophylactic antibiotics\n* contraindications for dental\u002Fsurgical procedures.",{"count":294,"type":22},120,"Peri-implantitis is a chronic inflammatory disease characterized by plaque-associated inflammation of the peri-implant mucosa and progressive loss of supporting bone around dental implants, which may ultimately lead to implant failure if left untreated.\n\nIt has been demonstrated that cellular and molecular responses of the host immune defense system play a critical role in the pathogenesis of peri-implantitis. Macrophages are key cells in the host immune response and are generally classified into two phenotypes: pro-inflammatory (M1) and anti-inflammatory (M2). While M1 macrophages are actively involved in the early defense response, a shift toward the M2 phenotype is required for the resolution of inflammation and tissue repair.\n\nSmoking has been shown to adversely affect macrophage polarization and function, thereby exacerbating inflammatory responses. Therefore, in the present study, levels of soluable CD163 (sCD163), B cell activating factor (BAFF), tumor necrosis factor-like weak inducer of apoptosis (TWEAK), a proliferation-inducing ligand (APRIL), interferon-gamma (IFN-γ), interleukin-10 (IL-10), interleukin-34 (IL-34), interleukin-35 (IL-35), and arginase activity (ornithine levels) will be evaluated in peri-implant health and peri-implantitis patients with varying disease severity and different smoking statuses. In addition, a comprehensive proteomic analysis will be performed to investigate the relationships among peri-implantitis severity, smoking, and macrophage polarization-related molecules. Baseline periodontal and peri-implant parameters will be recorded for all participants. In the peri-implant health group, tissue samples will be collected during exposure surgery performed for submerged implants, after which participants will be enrolled in supportive peri-implant care. Participants diagnosed with peri-implantitis will receive non-surgical therapy, during which tissue samples will be collected. Periodontal and peri-implant parameters will be reassessed for all participants at baseline, and at 6 and 12 weeks. Healthy peri-implant samples will be collected from submerged implants during exposure surgery. Peri-implantitis samples (probable pocket depth ≥ 6 mm with bleeding on probing) will be obtained during non-surgical therapy using a single stroke along the pocket wall.",[30],[298,299,300],"peri-implantitis","smoking","macrophage","2026-05-10",{"date":303,"type":42},"2026-05-13",{"date":305,"type":22},"2026-04",{"date":307,"type":22},"2028-09",{"name":309,"class":49},"Biruni University",{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":4,"eligibilityCriteria":316,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":317,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":319,"conditions":320,"keywords":322,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":334,"locationsCount":4},"100635805","access-to-probing-and-peri-implant-diseases-100635805","NCT07557459","Access to Probing and Peri-implant Diseases","Access to Peri-implant Probing and Its Association With Peri-implant Diseases: A Multicenter Cross-Sectional Study","Inclusion Criteria:\n\n* Age ≥18 years\n* Dental implants loaded for at least 3 years\n* Implant-supported restorations (single, partial fixed, or full-arch)\n* First visit to the clinic (maintenance, review, or treatment)\n* Signed informed consent\n* Availability of clinical and radiographic records\n\nExclusion Criteria:\n\n* Exposure of the intraosseous portion of the implant\n* Evident prosthetic misfit\n* Inability to provide informed consent\n* Lack of cooperation for clinical examination",{"count":318,"type":22},281,"This multicenter cross-sectional study aims to evaluate the association between access to peri-implant probing and radiographic peri-implant bone loss. Although probing is the primary diagnostic tool for peri-implant diseases, prosthetic design may limit access, potentially affecting diagnosis and disease progression. The study will include patients with dental implants in function for at least three years and will assess clinical, radiographic, and prosthetic variables.",[30,321],"Peri-implant Bone Loss",[30,155,323,324,325,326,327],"Probing","Bone Loss","Prosthetic Design","Oral Hygiene","Cross-sectional Study","2026-05-08",{"date":330,"type":42},"2026-05-12",{"date":332,"type":22},"2026-05",{"date":185,"type":22},{"name":335,"class":80},"Arrow Development",{"id":337,"slug":338,"hasResults":12,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":343,"targetDuration":4,"studyType":23,"phases":345,"briefSummary":346,"conditions":347,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":50},"100623020","crown-removal-in-non-surgical-peri-implantitis-therapy-a-randomized-trial-100623020","NCT07391202","Crown Removal in Non-Surgical Peri-Implantitis Therapy: A Randomized Trial","Effectiveness of Non-Surgical Mechanical Therapy of Peri-Implantitis With or Without Prosthetic Crown Removal: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients with at least one implant diagnosed with peri-implantitis (Berglundh et al., 2018);\n* Patients with a crown on the implant affected by peri-implantitis that is removable;\n* Patients who have not received non-surgical peri-implant therapy in the previous 6 months;\n* Patients who have not taken systemic antibiotic therapy in the previous 3 months.\n\nExclusion Criteria:\n\n* Full-Mouth Plaque Score (FMPS) \\> 30% at the time of non-surgical therapy;\n* Pregnant or breastfeeding women;\n* Relevant medical history, in the opinion of the examining clinician, that could affect the outcome of non-surgical peri-implant therapy;\n* Smoking patients consuming \\> 10 cigarettes\u002Fday.",{"count":344,"type":22},36,[25],"The aim of this single-blind, randomized controlled clinical trial is to evaluate whether removal of the prosthetic crown influences the clinical effectiveness of non-surgical mechanical therapy in implants affected by peri-implantitis.\n\nThe study is designed to compare changes in several clinical and radiographic parameters between baseline and follow-up examinations at 3, 6, and 12 months. The primary outcome measure will be the mean peri-implant probing depth (PIPD). Secondary outcomes will include changes in gingival recession (REC), radiographic marginal bone level (MBL), modified bleeding index (mBI), and additional patient-related variables.",[30],"2026-05-02",{"date":350,"type":42},"2026-05-07",{"date":352,"type":42},"2026-04-20",{"date":354,"type":22},"2027-07-31",{"name":356,"class":49},"G. d'Annunzio University",{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":17,"sex":18,"minAge":364,"maxAge":4,"enrollmentInfo":365,"targetDuration":4,"studyType":23,"phases":367,"briefSummary":368,"conditions":369,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":286},"100366523","peri-implantitis-implantoplasty-treatment-100366523","NCT04052373","Peri-implantitis Implantoplasty Treatment","Surgical Peri-implantitis Treatment With and Without Implantoplasty","Inclusion Criteria:\n\n* Peri-implantitis (according to 2018 criteria) on minimum 2 implants of similar surface and defect type\n* Competent to give consent\n* Exposed, modified implant surface with loss \\>2mm\n\nExclusion Criteria:\n\n* Previous radiotherapy to the jaws, current use of chemotherapy, systemic long-term corticosteroid treatment\n* Present or past use of bisphosphonate treatment • Pregnant or nursing subjects\n* Patients classified as \\> class II according to ASA classification\n* Implant unavailable for implantoplasty treatment\n* Inhability to comprehend and respond to the quality of life questionnaire\n* Examiners\u002Foperators deem original placement of implant (angle, position) suboptimal and considered to play a major role in development of peri-implantitis\n* History of peri-implantitis surgery prior to 6 months of screening","20 Years",{"count":366,"type":22},35,[25],"This double arm, split-mouth, single centre, controlled, randomised clinical study is designed to examine the effect of implantoplasty in treatment of peri-implantitis.\n\nPeri-implantitis will be treated with open flap debridement, with or without implantoplasty.",[64,370],"Peri-implant Mucositis","2026-04-28",{"date":373,"type":42},"2026-04-29",{"date":375,"type":42},"2019-10-15",{"date":377,"type":22},"2027-06-15",{"name":379,"class":49},"University of Oslo",{"id":381,"slug":382,"hasResults":12,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":4,"eligibilityCriteria":386,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":387,"targetDuration":4,"studyType":23,"phases":389,"briefSummary":390,"conditions":391,"keywords":392,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":50},"100635241","peri-implantitis-management-surgical-and-maintenance-outcomes-100635241","NCT07550127","Peri-implantitis Management: Surgical and Maintenance Outcomes","Impact of Implantoplasty on Local and Systemic Inflammation in Peri-implantitis: A Randomized Controlled Trial","Inclusion Criteria\n\nTo be enrolled the participant must met the following inclusion criteria:\n\n1. Aged 18 or older.\n2. In good general health, classified as ASA Physical Status I or II.\n3. Diagnosed with peri-implantitis requiring resective surgical treatment, characterized by: Bleeding on probing (BOP) around dental implants. Probing pocket depths (PPD) greater than 6 mm. Implants in function for over 1 year with progressive bone loss exceeding 3 mm. Initial screening confirmed by panoramic radiographs, cone-beam computed tomography (CBCT), and clinical diagnosis.\n\nTo be enrolled in the maintenance phase, participants must meet clinical stability criteria at the time of enrollment:\n\n* Probing depth (PD) ≤ 5 mm\n* Bleeding on probing (BOP) ≤ 1 point\n* Absence of suppuration (SOP)\n* Absence of progressive bone loss compared to pre-treatment bone levels\n\nExclusion Criteria:\n\n1. Patients with autoimmune or systemic inflammatory diseases (e.g., lupus, rheumatoid arthritis) that could alter immune cell profiles independent of local peri-implant inflammation.\n2. Chronic use of systemic corticosteroids or immunosuppressants within the past 3 months.\n3. Uncontrolled diabetes (HbA1c \\> 7.5%) due to its potential impact on healing and immune response.\n4. Active infection or antibiotic use in the 30 days prior to baseline sampling.\n5. Pregnancy or breastfeeding.\n6. Inability to undergo venipuncture or tolerate soft tissue biopsy.\n7. Inability to attend the 3-month follow-up visit or comply with study protocol.\n8. History of malignancy requiring systemic therapy within the past 5 years.",{"count":388,"type":22},44,[25],"The goal of this clinical trial is to learn how two standard surgical treatments for peri-implantitis affect inflammation around dental implants. Participants will be randomly assigned to receive resective surgery with implantoplasty or resective surgery with mechanical debridement only. Participants will provide blood samples before surgery, about 48 hours and 2 weeks after surgery. Participants will also provide a small gum tissue sample and fluid from around the implant at baseline and about 3 months after surgery. Participants will be followed in a maintenance program for up to 5 years.",[30],[30,393,394],"Implantoplasty","Single-cell RNA sequencing","2026-04-27",{"date":397,"type":42},"2026-05-01",{"date":399,"type":42},"2026-02-16",{"date":401,"type":22},"2029-06-30",{"name":403,"class":49},"University of Pittsburgh",{"id":405,"slug":406,"hasResults":12,"nctId":407,"briefTitle":408,"officialTitle":408,"acronym":4,"eligibilityCriteria":409,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":410,"targetDuration":412,"studyType":92,"phases":4,"briefSummary":413,"conditions":414,"keywords":415,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":420,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":424,"locationsCount":286},"100608983","long-term-stability-of-peri-implantitis-treatments-a-3-year-clinical-evaluation-100608983","NCT07208643","Long-term Stability of Peri-implantitis Treatments: a 3-year Clinical Evaluation","Inclusion Criteria:\n\n* 1\\. Patiens previously enrolled in the randomized clinical trial PER-ECL-2019-05, which included 36 patients with advanced peri-implantitis.\n\n  2\\. Completion of the original study protocol, including either reconstructive surgical therapy following a non-surgical phase or non-surgical therapy alone.\n\n  3.Signed informed consent for participation in the follow-up assessment.\n\nExclusion Criteria:\n\n* 1.Did not complete the original clinical trial protocol (PER-ECL-2019-05) or withdrew before final evaluation.\n\n  2.Had the implant removed due to complications unrelated to peri-implantitis progression.\n\n  3.Have developed systemic diseases or conditions (e.g., uncontrolled diabetes, immunosuppression, malignancy) that may affect periodontal or peri-implant tissue healing or confound clinical outcomes.\n\n  4.Are currently undergoing antibiotic or antiresorptive therapy (e.g., bisphosphonates) that could interfere with bone metabolism.\n\n  5.Are pregnant or breastfeeding at the time of the follow-up visit. 6.Are unwilling or unable to attend the clinical follow-up appointment or provide informed consent.",{"count":411,"type":22},34,"3 Years","This prospective study will include patients previously enrolled in the PER-ECL-2019-05 trial who attend the Department of Periodontology (CUO) for maintenance therapy or treatment of periodontal and\u002For peri-implant diseases, provided they meet the inclusion criteria.\n\nInitially, 36 patients with advanced peri-implantitis were enrolled in a randomized clinical trial evaluating the clinical, radiographic and patient-related outcomes of reconstructive therapy following a non-surgical phase of peri-implantitis treatment compared to non-surgical treatment alone (PER-ECL-2019-05) (10).\n\nAt the study conclusion 34 patients were re-evaluated and 2 patients were excluded from the study (10).\n\nIn the original study, adult patients presenting at least one titanium implant diagnosed with peri-implantitis were identified among patients referred to the Department of Periodontology of UIC between January 2020 and October 2022. Peri-implantitis was diagnosed following the case definition of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions (11) that is, PPD ≥ 6 mm combined with bleeding on probing (BOP) and\u002For suppuration (SUP), together with progressive bone loss in relation to the radiographic bone level assessment. In those cases where initial radiograph was unavailable, the definition of a peri-implantitis case was based on radiographic evidence of bone level ≥3 mm apical to the most coronal portion of the intra-osseous part of the implant (12).\n\nAt the outset of the original study, participants were randomly assigned to one of two groups:\n\nThe first group received only non-surgical therapy for peri-implantitis, while the second group underwent a non-surgical phase followed by reconstructive surgical treatment. This design allowed for direct comparison of the clinical, radiographic, and patient-centered outcomes between the two treatment modalities. Both groups were managed and evaluated according to standardized protocols, ensuring consistency and reliability of the results at 12 months .\n\nPatients who have not returned to the Department will be contacted by telephone and invited to participate through the academic office.\n\nAt 36 months, a single follow-up will be carried out including:\n\nA detailed clinical examination. A standardized radiographic assessment.",[30],[30,230,416,417,418,419],"Reconstructive therapy","Maintenance therapy","Prospective study","flapless treatment",{"date":371,"type":42},{"date":422,"type":42},"2026-04-01",{"date":397,"type":22},{"name":425,"class":49},"Ramón Pons Calabuig",{"id":427,"slug":428,"hasResults":12,"nctId":429,"briefTitle":430,"officialTitle":431,"acronym":4,"eligibilityCriteria":432,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":433,"enrollmentInfo":434,"targetDuration":4,"studyType":23,"phases":435,"briefSummary":436,"conditions":437,"keywords":438,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":449,"locationsCount":50},"100508400","comparison-of-the-effectiveness-of-two-different-surgical-therapeutic-protocols-of-peri-implantitis-100508400","NCT05899933","Comparison of the Effectiveness of Two Different Surgical Therapeutic Protocols of Peri-implantitis","Implantoplasty Versus Implant Decontamination With Erythritol Air-abrasive Device During Surgical Therapy of Peri-implantitis. Clinical, Radiographic and Microbiological Evaluation. A Randomized Controlled Clinical Study","Inclusion Criteria:\n\nGeneral Inclusion Criteria:\n\n* Participants ≥ 18 years and ≤ 80 years of age\n* Non-smokers based on the patients' self-reported smoking status, defined as patients who had never smoked or had quit smoking at least 2 years ago\n* Implants in function for more than 1 year after suprastructure connection\n\nInclusion Criteria for implants diagnosed with Peri-Implantitis:\n\n* Presence of at least one implant diagnosed with peri-implantitis defined as presence of bleeding on probing and\u002For suppuration, probing pocket depth ≥6 mm and ≥3 mm of detectable bone loss after initial re-modelling\n* Absence of implant mobility\n\n  * in participants with more than one implant, the implant with the worst clinical condition will be studied.\n\nInclusion Criteria for implants diagnosed with Peri-Implant Health:\n\n* Absence of peri-implant signs of inflammation (redness, swelling)\n* Lack of bleeding on probing\n* Absence of bone loss beyond crestal bone level changes resulting from initial remodeling, which should not be ≥2 mm\n\nExclusion Criteria:\n\n* Smokers\n* Uncontrolled diabetes mellitus (HBA1c \\>7)\n* Treatment with bisphosphonates\n* Needing antibiotic prophylaxis\n* Currently pregnant or breast-feeding women\n* History of systemic administration of antibiotic treatment during the preceding 3 months\n* Systemic conditions that contraindicate treatment\n* Use of medications known to induce gingival hyperplasia","80 Years",{"count":196,"type":22},[25],"The purpose of the present study is to compare the 1-year clinical, radiographic and microbiological outcomes and patients' satisfaction following surgical treatment of peri-implantitis after applying two different surface modification methods. Secondarily, analysis and comparison of the microbiological results of implants diagnosed and treated for peri-implantitis with healthy implants will be performed.",[64,95],[64,439,393,440,441,442],"Surgical therapy","Air-abrasive device","Erythritol powder","Peri-Implant microbiota","2026-04-14",{"date":445,"type":42},"2026-04-15",{"date":447,"type":42},"2023-07-28",{"date":183,"type":22},{"name":450,"class":49},"National and Kapodistrian University of Athens",{"id":452,"slug":453,"hasResults":12,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":457,"eligibilityCriteria":458,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":23,"phases":461,"briefSummary":462,"conditions":463,"keywords":466,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":50},"100568289","surgical-treatment-of-peri-implantitis-with-adjunctive-application-of-platelet-rich-fibrin-prf-100568289","NCT06679283","Surgical Treatment of Peri-implantitis With Adjunctive Application of Platelet Rich Fibrin (PRF)","Surgical Treatment of Peri-implantitis With Adjunctive Application of Platelet Rich Fibrin (PRF) Compared With Open Flap Debridement (OFD) Alone: A 12-month Randomised Clinical Trial","PRF","Inclusion Criteria:\n\n1. One or more peri-implant sites with PPD ≧ 5 mm combined with BOP\u002Fsuppuration and\n2. Peri-implant marginal bone loss, defined as a crater like defect ≧ 3 mm as assessed from intraoral radiographs\n3. Good oral hygiene i.e. a plaque index \\\u003C20%\n4. Written informed consent\n\nExclusion Criteria:\n\n1. History of chronic inflammatory disease\n2. Severe systemic diseases\n3. Medically confirmed diagnosis of diabetes mellitus\n4. Anti-inflammatory prescription including prednisone\n5. Smoking \\> 5 cigarettes\n6. Pregnant or lactating women\n7. \\\u003C 18 years of age",{"count":460,"type":22},40,[25],"Platelet-rich fibrin (PRF) is a second-generation platelet concentrate used for tissue and bone regeneration. PRF releases growth factors such as TGF-β, PDGF, VEGF, IGF, and FGF, which are known to promote wound healing and bone regeneration. Thus, PRF may offer a promising therapeutic approach for peri-implantitis treatment. Numerous studies have reported beneficial effects of PRF on bone regeneration, bone augmentation, soft tissue healing, and ridge preservation. In infrabony periodontal defects, PRF has shown significant improvements in pocket depth reduction, clinical attachment level (CAL) gain, and bone fill.\n\nHowever, a recent systematic review highlighted that evidence supporting PRF use in peri-implantitis remains limited, primarily due to a lack of adequately designed studies. Therefore, the aim of this project is to investigate whether PRF enhances regeneration in peri-implantitis defects. Specifically, it will assess whether surgical debridement of peri-implantitis defects-including electrochemical detoxification of implant surfaces using GalvoSurge-combined with PRF clot and membrane placement, improves treatment outcomes compared to surgical debridement and detoxification using GalvoSurge alone.\n\nFor this purpose, implants with peri-implantitis defects of comparable size will be randomly assigned to either the test or control group. After 12 months, implants will be clinically evaluated for radiographic defect fill, reduction in probing pocket depth (PPD), and bleeding on probing (BOP). The objective of this project is to verify, both radiographically and clinically, whether adjunctive PRF application enhances tissue regeneration and healing of peri-implantitis defects compared to open flap debridement (OFD) alone.",[64,464,465],"Bone Resorption","Platelet-Rich Fibrin",[467],"platelet rich fibrin, peri-implantitis","2026-03-24",{"date":470,"type":42},"2026-03-30",{"date":472,"type":42},"2025-02-01",{"date":474,"type":22},"2027-12-31",{"name":476,"class":49},"University of Bern",{"id":478,"slug":479,"hasResults":12,"nctId":480,"briefTitle":481,"officialTitle":482,"acronym":483,"eligibilityCriteria":484,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":485,"targetDuration":4,"studyType":23,"phases":487,"briefSummary":488,"conditions":489,"keywords":491,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":497,"lastUpdatePostDateStruct":498,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":504,"locationsCount":50},"100628847","minimally-invasive-non-surgical-therapy-of-peri-implantitis-100628847","NCT07466966","Minimally-Invasive Non-Surgical Therapy of Peri-Implantitis","Minimally-Invasive Non-Surgical Therapy of Peri-Implantitis: A Multicenter Randomized Controlled Trial (MINST vs NSPT)","MINST vs NSPT","Inclusion Criteria:\n\n* Age ≥18\n* Peri-implantitis diagnosis (PPD \\>6 mm, BOP+, bone loss ≥3 mm)\n* Accessible implant surface without removing suprastructure\n* FMPS \\\u003C30%, FMBS \\\u003C30-35%\n\nExclusion Criteria:\n\n* Antibiotics in last 3 months\n* Pregnancy\u002Flactation\n* Uncontrolled diabetes (HbA1c ≥7)\n* Long-term SPIC (\\>2 years)\n* Previous implant therapy \\\u003C12 months\n* Smoking\u002Fvaping in last 12 months\n* Hopeless implant\n* Need for adjunctive antibiotics",{"count":486,"type":22},106,[25],"This multicenter, single-masked randomized controlled clinical trial evaluates the effectiveness of minimally-invasive non-surgical therapy (MINST) compared with standard non-surgical peri-implant therapy (NSPT) in patients diagnosed with peri-implantitis. The study investigates clinical outcomes, radiographic bone levels, patient-reported outcomes, and treatment time over 12 months.",[30,490,226],"Periodontitis",[298,492,493,494,495,496],"MINST","non-surgical therapy","ultrasonic debridement","implant dentistry","randomised controlled trial","2026-03-11",{"date":499,"type":42},"2026-03-13",{"date":501,"type":42},"2026-01-01",{"date":503,"type":22},"2028-04",{"name":505,"class":49},"St. Anne's University Hospital Brno, Czech Republic",{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":4,"eligibilityCriteria":512,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":89,"enrollmentInfo":513,"targetDuration":4,"studyType":23,"phases":515,"briefSummary":516,"conditions":517,"keywords":519,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":524,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":529,"locationsCount":50},"100629185","adjunctive-keratinized-mucosa-augmentation-in-peri-implantitis-100629185","NCT07471386","Adjunctive Keratinized Mucosa Augmentation in Peri-Implantitis","Impact of Keratinized Mucosa Augmentation as an Adjunct to Non-Surgical Therapy in the Management of Peri-Implantitis","Inclusion Criteria:\n\n* Non-smoker\n* Systemically healthy\n* Keratinized mucosa witdh \\\u003C 2 mm\n\nExclusion Criteria:\n\n* İntake of medications that impede periodontal tissue health and healing\n* Pregnancy or lactation",{"count":514,"type":22},30,[25],"This study aims to increase the width and thickness of peri-implant keratinized mucosa (KM) by transferring a properly dimensioned free gingival graft (FGG) from the palatal donor site and to evaluate its effect as an adjunctive approach to non-surgical peri-implantitis therapy. The procedure is indicated for patients diagnosed with peri-implantitis who present with an inadequate KM (midbuccal KM height \\\u003C 2 mm). One month after non-surgical therapy, patients in the test group will undergo keratinized mucosa augmentation using an FGG, while patients in the control group will continue with supportive periodontal therapy and regular follow-up visits. The primary outcome measure of the study is the change in probing depth (PD) at 12 months following peri-implantitis treatment.",[30,518],"Soft Tissue Augmentation at Dental Implants",[30,520,521,522],"Free gingival graft","Inflamation","Soft tissue deficiency","2026-03-10",{"date":499,"type":42},{"date":526,"type":42},"2026-03-01",{"date":528,"type":22},"2027-06-01",{"name":108,"class":49},{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":535,"acronym":4,"eligibilityCriteria":536,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":537,"targetDuration":4,"studyType":23,"phases":538,"briefSummary":539,"conditions":540,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":541,"lastUpdatePostDateStruct":542,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":548,"locationsCount":50},"100617986","immediate-versus-delayed-surgical-reconstruction-of-peri-implantitis-intra-bony-defects-100617986","NCT07325747","Immediate Versus Delayed Surgical Reconstruction of Peri-implantitis Intra-bony Defects.","Immediate Versus Delayed Surgical Reconstruction of Peri-implantitis Intra-bony Defects: A Parallel-arm, Assessor-blind, Randomized, Controlled Clinical Trial","Inclusion Criteria:\n\n* Systemically healthy adults\n* Age ≥ 18 years\n* The patient must be able to perform good oral hygiene\n* With at least one implant with either cement or a screw-retained prosthesis demonstrating a diagnosis of peri-implantitis at an implant in function for a minimum of 1 year with a prosthesis installed.\n* In cases where previous radiographic records are available: presence of bleeding and\u002For suppuration on gentle probing, increased probing depth compared to previous examinations, and radiographic evidence of bone loss beyond initial crestal remodeling. (Berglundh 2018).\n* In cases where baseline radiographs are not available: presence of PPD ≥6 mm with BOP and\u002For suppuration (SUP) and radiographically detectable marginal bone loss (MBL) exceeding 3 mm on an implant in function forfor at least 1 year (Berglundh 2018).\n* Target implants have to also demonstrate the presence of a peri-implant intra-bony defect with a depth ≥3 mm and width ≤4 mm, as assessed on radiographs and confirmed intra-surgically. In addition, the bony defect should present with a minimum of two walls .\n\nNo implant mobility and no evidence of occlusal overload. In patients presenting with more than one implant meeting the inclusion criteria, a single implant will be randomly selected for inclusion in the study.\n\nExclusion Criteria:\n\n* Short implants (≤ 6mm)\n* Contraindications for undergoing oral surgery.\n* Patients pregnant or attempting to get pregnant (self-reported), or nursing women.\n* Untreated\u002Factive periodontitis, or other untreated acute infections at the surgical site.\n* Untreated malignancies at the surgical site.\n* Self-reported current smoking, or active tobacco chewing, or chronic vaping.\n* Taking long-term (\\>1yr) NSAID, prednisone or other anti-inflammatory prescription drugs\n* Patients with any known history of blood disorders or complications such as abnormal concentration of thrombin and factor XIII in plasma, or hemophilia.\n* Patients with significant co-morbidities, such as obesity, uncontrolled diabetes, immunosuppression, severe endocrine-induced bone diseases, signs of malnourishment, those receiving immunosuppressive therapy, poor tissue oxygenation or perfusion, and pre- or post-operative radiation.\n* Unable to give consent for participation.",{"count":460,"type":22},[25],"The purpose of this study is to test the comparative efficacy of two surgical approaches (immediate versus delayed GBR) for the surgical reconstruction of peri-implantitis intra-bony defects in terms of the clinical, radiographical, histological, volumetric, microbiological, and patient-reported outcomes.\n\nThe investigators hypothesize that in certain clinical situations, treatment of peri-implantitis intra-bony defects with the use of a compound bone grafting material (mixture of allogenic bone substitutes) and a non-resorbable barrier membrane and following a delayed approach (test group) with initial phase of defect decontamination and initial healing phase would yield superior outcomes to that of the conventional approach (control group) of defect decontamination and regeneration at the same clinical visit while also significantly enhancing patient-reported outcomes:\n\nH0: There is no difference between the two mentioned approaches in terms of the treatment outcomes. H1: There is a significant difference, favoring the delayed approach compared to the immediate reconstruction.",[123],"2026-02-05",{"date":543,"type":42},"2026-02-06",{"date":545,"type":42},"2026-01-12",{"date":547,"type":22},"2028-12",{"name":549,"class":49},"University of Michigan",{"id":551,"slug":552,"hasResults":12,"nctId":553,"briefTitle":554,"officialTitle":555,"acronym":4,"eligibilityCriteria":556,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":557,"targetDuration":4,"studyType":23,"phases":558,"briefSummary":559,"conditions":560,"keywords":561,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":563,"lastUpdatePostDateStruct":564,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":570,"locationsCount":4},"100621061","comparison-of-two-non-surgical-procedure-to-manage-gum-disease-around-implants-100621061","NCT07365722","Comparison of Two Non-surgical Procedure to Manage Gum Disease Around Implants.","Minimally-Invasive Non-Surgical Therapy Of Peri-implantitis: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Diagnosis of peri-implantitis (any implant surface\u002Fany amount of keratinized gingiva)\n* PPD\\>6mm at least in one implant surface\n* Bone levels ≥3mm apical of the most coronal portion of the intra-osseous part of the implant.\n* Implant surface deemed accessible by the treating clinician, without the need to remove the prosthetic suprastructure\n* Full-mouth plaque score \\\u003C30%\n* Full-mouth bleeding score \\\u003C30%\n\nExclusion Criteria:\n\n* A course of antibiotics within the past 3 months\n* Pregnant\u002Flactating women\n* Relevant medical history as evaluated by the examining clinician which may have the potential to affect periodontal surgical treatment (e.g., uncontrolled diabetes HbA1c≥7).\n* Individuals on long-standing (2 or above years) supportive peri-implant care (SPIC)\n* Previous non-surgical or surgical therapy of the affected implant within 12 months\n* Current smoking or vaping (defined as any smoking or vaping within 12 months)\n* Implant considered hopeless according to the treating clinician (e.g. mobility, circumferential bone loss \\>80%, implant outside the bone envelope)\n* Case needing adjunctive antibiotic therapy, according to the treating clinician",{"count":60,"type":22},[25],"Research Question:\n\nCan a minimally invasive, non-surgical treatment approach (MINST) be more effective than the current standard non-surgical method in treating peri-implantitis, a common inflammatory condition affecting dental implants?\n\nBackground:\n\nDental implants are widely used to replace missing teeth. While they are usually successful, some patients develop a condition called peri-implantitis, an infection that causes inflammation and bone loss around the implant. This can eventually lead to implant failure if not treated properly. Currently, non-surgical treatments are used to clean the area and reduce inflammation. However, these methods often fall short of fully resolving the issue, and many patients require further treatment or even surgery.\n\nA newer approach called MINST (Minimally-Invasive Non-Surgical Therapy) has shown promising results for treating gum disease around natural teeth. This method focuses on precision cleaning with minimal trauma to the surrounding tissues, reducing pain and improving healing. While MINST works well for gum disease, its effectiveness for treating peri-implantitis has not yet been tested.\n\nPurpose of the Study:\n\nThis clinical trial will compare the effectiveness of MINST with the standard non-surgical treatment currently used for peri-implantitis.\n\nThe aim is to determine whether MINST can better treat the disease, improve healing, and reduce discomfort for patients.\n\nHypotheses:\n\nAlternate Hypothesis (What we expect to find): MINST will result in better outcomes, specifically, fewer deep pockets around the implant, less bleeding, and fewer signs of infection, compared to the standard treatment.\n\nNull Hypothesis: There will be no significant difference between the outcomes of the two treatment approaches.\n\nStudy Design:\n\nType of Study: A randomized controlled trial (RCT) involving 106 patients. Duration: Patients will be followed for 12 months after treatment. Locations: Multiple dental centers participating in the trial. Method: Half of the participants will receive MINST; the other half will receive the standard treatment. Neither patients nor outcome assessors will know which treatment was used (single-masked). What Will Be Measured? Primary Goal: To see how many patients show healing (defined as smaller pockets, little or no bleeding, and no pus) 12 months after treatment.\n\nSecondary Goals:\n\nPatient-reported outcomes, including pain levels and quality of life Changes in pocket depth and tissue attachment Bacterial changes Time taken for treatment appointments Why Is This Important? If MINST proves to be more effective and comfortable for patients, it could change how peri-implantitis is managed in the future- potentially reducing the need for surgery, improving patient experience, and helping more people keep their dental implants for longer.",[123],[562],"peri implantitis","2026-01-19",{"date":565,"type":42},"2026-01-26",{"date":567,"type":22},"2026-02-01",{"date":569,"type":22},"2028-02-07",{"name":571,"class":49},"King's College London",{"id":573,"slug":574,"hasResults":12,"nctId":575,"briefTitle":576,"officialTitle":577,"acronym":578,"eligibilityCriteria":579,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":580,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":582,"conditions":583,"keywords":584,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":563,"lastUpdatePostDateStruct":588,"startDateStruct":590,"completionDateStruct":592,"leadSponsor":594,"locationsCount":286},"100426288","periodontitis-and-inflammation-100426288","NCT04831060","Periodontitis and Inflammation","Characterization of the Immuno-inflammatory Response Involved in Bone Destruction During Periodontitis: Study With Biological Collection","CB-PARO","Inclusion Criteria:\n\nCommon criteria for all patient groups\n\n* Patient \\> 18 years old\n* Patient affiliated to a social security system, beneficiary or beneficiary of a right other than AME\n* Patient who speaks and understands French well enough to be able to read and understand the study information note.\n* Patient who does not object to his participation in the study\n\nSpecific criteria:\n\n\\- Case Periodontitis: Patient with localized or generalized periodontitis, stage 3 or 4. The diagnosis of periodontitis is based on the elements found during the interview and clinical examination\n\n\\- Case peri-implantitis: Patients with at least 1 implant affected by peri-implantitis. Diagnosis is based on the findings of the interview, clinical examination and radiographic examination.\n\nControl group:\n\nPatient with gingival health on intact or reduced periodontium with no history of periodontitis or peri-implantitis and requiring surgical care such as dental avulsion and pre-prosthetic periodontal corrective\u002Faesthetic surgeries (coronal elongation, neck alignment.)\n\nExclusion Criteria:\n\n* Patients who have received antibiotic prophylaxis, antibiotic therapy, or anti-inflammatory treatment within 3 months prior to inclusion\n* Pregnant or breastfeeding women\n* Patient included in another interventional research protocol or in a period of exclusion.\n* Patients under guardianship, curatorship or legal protection.\n* Patient having expressed his opposition to participate in the research",{"count":581,"type":22},219,"Today, to understand pathogenic mechanisms involved in periodontitis and peri-implantitis remains a challenge to identify biomarkers or therapeutic targets to improve prevention and screening, as well as the effectiveness of periodontitis and peri-implantitis treatments. The aim is to characterize, in vivo, specific molecular markers reflecting the activity of the pathology, which could lead to\n\n* improve the knowledge of the pathogenesis of periodontitis and peri-implantitis;\n* determine target molecules involved in tissue destruction;\n* determine molecular profiles of patients at local and systemic risk;\n* determine therapeutic targets\n\nFor this purpose, biological samples will be collected (plaque, saliva, crevicular fluid) from patients with periodontitis or peri-implantitis stage 3 or 4 versus patients with a healthy periodontium. Biological samples will be collected before and all along the periodontal or peri-implantal treatment. Gingiva explants collection will be sampling within the surgical procedures (if they are needed).\n\nThe primary objective is to investigate tissue and cellular expression of molecular markers associated with periodontal destruction during periodontitis or peri-implantitis in relation to periodontal infection and systemic changes in host response. A characterization of the cytokines in gingival fluid and unstimulated saliva (Luminex® technique) of patients with periodontitis or peri-implantitis versus without periodontitis or peri-implantitis will be done.\n\nThe secondary objective is to study the influence of periodontitis on systemic pathologies via serum analysis of molecules and bacteria involved in periodontal destruction. Immunofluorescence evaluation of protein expression and distribution (inflammatory mediators, inflammatory pathway signaling proteins) in gingival explants, characterization of proteases (MMP) present in gingival fluid and unstimulated saliva (Luminex® technique) and microbiological analysis of the subgingival biofilm (by quantitative PCR).",[490,64],[490,585,586,587,298],"Inflammation","Cytokines","Diabetes Mellitus",{"date":589,"type":42},"2026-01-21",{"date":591,"type":42},"2023-02-15",{"date":593,"type":22},"2028-11-15",{"name":595,"class":49},"Assistance Publique - Hôpitaux de Paris",{"id":597,"slug":598,"hasResults":12,"nctId":599,"briefTitle":600,"officialTitle":601,"acronym":4,"eligibilityCriteria":602,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":117,"enrollmentInfo":603,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":605,"conditions":606,"keywords":607,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":611,"lastUpdatePostDateStruct":612,"startDateStruct":614,"completionDateStruct":616,"leadSponsor":617,"locationsCount":4},"100614527","evaluation-of-25ohd3-and-ll-37-levels-in-periimplant-sulcus-fluid-100614527","NCT07280754","Evaluation of 25(OH)D3 and LL-37 Levels in Periimplant Sulcus Fluid","Evaluation of 25(OH)D3 and LL-37 Levels in Peri-implant Sulcus Fluid in Peri-implant Diseases","Inclusion Criteria:\n\n* Being between the ages of 18-65,\n* Having dental implants and using implant-supported prostheses for at least one year,\n* Not having used systemic and\u002For topical antibiotics\u002Fanti-inflammatory drugs or mouthwashes in the last three months,\n* Not having received periodontal\u002Fperi-implant treatment in the last six months.\n\nExclusion Criteria:\n\n* Having a systemic disease or condition that affects peri-implant status,\n* Having a metabolic bone disease,\n* Bruxism,\n* Being pregnant or lactating,\n* Having received periodontal\u002Fperi-implant treatment within the last 6 months,\n* Smoking and alcohol use,\n* Taking vitamin D supplements.",{"count":604,"type":22},72,"Despite technological advances that have significantly improved dental implant osseointegration and survival rates, biological complications such as peri-implantitis and peri-implant mucositis are common around the implant. The active form of vitamin D, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), can be induced by the expression of leucine-lysine-37 (LL-37), a human antimicrobial peptide in the cathelicidin family. Studies have shown that 1,25(OH)2D3 and its precursor, 25(OH)D3, significantly reduce inflammation by suppressing the release of receptor activator nuclear factor kappa b ligand (RANKL), tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1, and IL-6, and by preventing alveolar bone loss. To date, many cytokines have been investigated in peri-implant sulcus fluid (PIOS). The lack of a direct study investigating vitamin D and LL-37 levels in PIOS constitutes the unique value of this project. This study aims to compare LL-37 and 25(OH)D3 levels in PIOS and examine their correlation with markers such as IL-6, IL-10, and MMP-8, as well as clinical parameters. Volunteers aged 18-65 who have received dental implants at the Recep Tayyip Erdoğan University Faculty of Dentistry and have been using their implant-supported prosthesis for at least one year and who have been informed about this study will be included in the study. The groups will be formed as peri-implant health, peri-implant mucositis, and peri-implantitis. The implants of the patients included in the study will be evaluated for probed pocket depth (PPD), clinical attachment level (CAL), suppuration (S), modified gingival index (mGI), plaque index (mPI), bleeding index (mBI), keratinized gingival amount, and attached gingival amount. PIOS and serum samples will be obtained from patients, and their relationship to periodontal status and each other will be statistically evaluated.\n\nThis project may help discover new biomarkers that can be used in the early diagnosis of peri-implantar diseases. This study could contribute to earlier treatment, lower patient costs, and even the development of new treatment plans for these diseases.",[123,96],[608,609,298,610],"LL-37","peri-implanter sulcus fluid","vitamin D","2025-12-12",{"date":613,"type":42},"2025-12-19",{"date":615,"type":22},"2025-12-30",{"date":104,"type":22},{"name":618,"class":49},"Recep Tayyip Erdogan University",{"id":620,"slug":621,"hasResults":12,"nctId":622,"briefTitle":623,"officialTitle":623,"acronym":624,"eligibilityCriteria":625,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":626,"targetDuration":4,"studyType":23,"phases":627,"briefSummary":628,"conditions":629,"keywords":630,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":632,"lastUpdatePostDateStruct":633,"startDateStruct":635,"completionDateStruct":637,"leadSponsor":639,"locationsCount":50},"100607666","efficacy-of-photodynamic-therapy-in-the-non-surgical-treatment-of-peri-implantitis-100607666","NCT07191522","Efficacy of Photodynamic Therapy in the Non-Surgical Treatment of Peri-Implantitis","PeriimpMAA","Inclusion Criteria:\n\n* patients over 18 years of age;\n* patients with one or more implants diagnosed with peri-implantitis rehabilitated for at least one year;\n* PI and GI \\\u003C 25%.\n\nExclusion Criteria:\n\n* smoking patients;\n* patients with uncontrolled periodontitis;\n* systemic diseases that influence the study (diabetes);\n* inadequate prosthetic rehabilitation that cannot be modified or that prevents access for physical decontamination;\n* implants rehabilitated with cemented crowns;\n* pregnant and lactating women;\n* previous surgical intervention at the same site;\n* therapy with non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics or immunosuppressants in the last 3 months;\n* patients previously undergoing chemotherapy or radiotherapy;\n* PI and IG \\> 25%;\n* uncooperative patients.",{"count":460,"type":22},[25],"Peri-implantitis is a growing public health problem that can lead to several complications and sequelae, with a serious impact on the health and quality of life of patients and a high cost for healthcare systems.\n\nBacterial plaque that accumulates around dental implants leads to peri-implant tissue inflammation that ultimately can result in the loss of the implant, significant bone destruction and infection that can reach other regions. Successful implant decontamination is necessary to preserve the implant and several strategies have been suggested for this purpose, however, there is still no fully effective treatment modality and failures and recurrence are relatively frequent.\n\nTo better understand this problem and develop more effective treatment strategies, investigators will first conduct an epidemiological study to understand the factors associated with the development of this pathology. Although there is data at an international level, the incidence of this problem in Portugal has not yet been properly studied. Later investigators will conduct a randomized clinical trial to evaluate the 6-week clinical outcomes of patients treated with a photodynamic therapy as an adjuvant versus the use of conventional titanium implant curettes for implant surface decontamination in the non-surgical treatment. Sixty patients\u002Fimplants with peri-implantitis and within the established criteria, will undergo non-surgical treatment with one of the two protocols being studied. Various clinical and radiographic parameters will be evaluated, such as probing depth, insertion loss, recession, bleeding on probing, suppuration, peri-implant crevicular fluid volume, alveolar bone loss and peri-implantitis microbiome will be evaluated before surgery and 6 weeks after surgery.",[123],[30,631],"Antimicrobial Photodynamic Therapy","2025-09-23",{"date":634,"type":42},"2025-09-25",{"date":636,"type":42},"2025-05-14",{"date":638,"type":22},"2027-07-30",{"name":640,"class":49},"Egas Moniz - Cooperativa de Ensino Superior, CRL"]